SCHEMBL4456536

SCHEMBL4456536

c1ccc(OCc2nc(-c3ccc(Nc4cccs4)cc3)c[nH]2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.37
PTGS2 P35354 1/20 0.35
RAB9A P51151 9/20 0.35
NPC1 O15118 7/20 0.35
SMN1; SMN2 Q16637 6/20 0.35
MAPT P10636 4/20 0.35
ALOX5 P09917 4/20 0.35
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
GAA P10253 3/20 0.33
NFKB1 P19838 2/20 0.33
NFKB2 Q00653 2/20 0.33
RELA Q04206 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MCL1 Q07820 1/20 0.33
RECQL P46063 1/20 0.33
IKBKB O14920 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4453029 0.86 RAB9A (0.40) PTGS2RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4453028 0.84 F2 (0.40) RAB9ANPC1SMN1; SMN2TP53TSHR
SCHEMBL4470351 0.81 IKBKB (0.42) SYKRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL4466562 0.79 RAB9A (0.45) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL4456488 0.78 ENPP3 (0.35) SYKRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4460180 0.78 ENPP3 (0.35) SYKRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4464942 0.77 SCN5A (0.36) SYKRAB9ANPC1SMN1; SMN2MEN1
SCHEMBL4686964 0.77 MCL1 (0.46) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL5750527 0.77 LMNA (0.44) PTGS2RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL4461716 0.76 SYK (0.40) SYKRAB9ANPC1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed
EP-1638943-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-03-29 EP disclosed
WO-2004106307-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 SYK 413/4885PTGS2 234/4885RAB9A 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.